Dr. Jones is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2801 L St
Ste 10
Sacramento, CA 95816Phone+1 916-454-1225Fax+1 916-454-6618
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 1987 - 1990
- Loyola Medicine MacNeal HospitalInternship, Transitional Year, 1986 - 1987
- Rush Medical College of Rush University Medical CenterClass of 1986
Certifications & Licensure
- CA State Medical License 1991 - 2025
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
- RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
- Join now to see all
Publications & Presentations
PubMed
- 744 citationsRadiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialMaura L. Gillison, Andy Trotti, Jonathan Harris, Avraham Eisbruch, Paul M. Harari
Lancet. 2019-01-05 - 3568 citationsRadiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and NeckJames A. Bonner, Paul M. Harari, Jordi Giralt, Nozar Azarnia, Dong M. Shin
The New England Journal of Medicine. 2006-02-09 - 1345 citationsRadiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-indu...James A. Bonner, Paul M. Harari, Jordi Giralt, Roger B. Cohen, Christopher U. Jones
The Lancet. Oncology. 2010-01-01
Committees
- Member, Co-author, Committee on Appropriateness Criteria, Expert Panel on Radiation Oncology - Head & Neck Cancer, American College of Radiology 2015 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: